OncoCyte Corp reports results for the quarter ended in March - Earnings Summary

Insight Molecular Diagnostics

11/05/2023 14:32

* OncoCyte Corp  OCX.OQ  reported quarterly adjusted
earnings of 2
cents​​ per share for the quarter ended in March. The mean
expectation of five analysts for the quarter was for a loss of 8
cents per share.
    * Revenue fell 79.2% to $297.00 thousand from a year ago;
analysts
expected $346.40 thousand. 
    * OncoCyte Corp's reported EPS for the quarter was 2 cents​.
    * The mean earnings estimate of analysts had risen by
about 8.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * OncoCyte Corp shares had fallen by 24.7% this quarter and
lost 16.9% so far this year.
    * The company reported quarterly net income of $2.4 million.
    * Wall Street's median 12-month price target for OncoCyte
Corp is
$0.45 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.08          0.02           Beat
 Dec. 31 2022      -0.09          -0.40          Missed
 Sep. 30 2022      -0.11          -0.08          Beat
 Jun. 30 2022      -0.12          -0.07          Beat